Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

SABS US Equity

SAB Biotherapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1833214 · FY ends Dec 31
$3.78
-0.01 (-0.26%)
USD · as of 2026-08-19 · marketstack
1 8-K filing · 1 13D · 7 13G
DateEventWhat happened / filerSource
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by PERCEPTIVE ADVISORS LLCsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Caligan Partners LPsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Commodore Capital LPsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Vivo Opportunity Fund Holdings, L.P.sec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by Woodline Partners LPsec.gov ↗
2026-08-1413G/ASchedule 13G amendment — ≥5% beneficial owner (passive) · by BALYASNY ASSET MANAGEMENT L.P.sec.gov ↗
2026-08-1213GSchedule 13G filed — ≥5% beneficial owner (passive) · by Adage Capital Management, L.P.sec.gov ↗
2026-08-1013D/ASchedule 13D amendment — ≥5% beneficial owner (active intent) · by RA CAPITAL MANAGEMENT, L.P.sec.gov ↗
2026-07-078-K 7.01Regulation FD disclosuresec.gov ↗
Source: SEC EDGAR (public domain) · history starts 2026-07-07

Every row is a filed document, checked against its EDGAR index.